Company Overview and News
Shopify (NYSE:SHOP) is an absolute firecracker and the stock has quintupled in the past few years. But the journey for this company is only beginning. This article will be a deep dive into the qualitative aspects of Shopify and why it looks to be a fantastic business for many years to come. First, we will take a brief look at the CEO, then dive into the details of the business, looking at its innovation and company culture, moving on to risks and ending with a look at the financials.
TWLO SHOP BUD AMZN TSLA ADBE
Baozun (NASDAQ:BZUN), Chinese e-commerce solution provider, has had its stock price more than triple in the past year. Wall Street has taken a while to realize the business model shift the company has gone through in the past couple years but this article will provide the good, the bad and the beautiful on Baozun.
JD BABA SHOP BZUN AMZN
What a run it has been for Etsy Inc (NASDAQ:ETSY). The online craft marketplace has been on a tear of late. Etsy stock now has tripled over the past year, with a 208% gain the 19th best among the nearly 1,900 stocks with a market capitalization over $2 billion.
MIK SQ SHOP AMZN SQNXF ETSY EBAY
The downgrade of Hershey Co (NYSE:HSY) by Credit Suisse AG (NASDAQ:TVIX) has attracted attention. Analyst Robert Moskow downgraded Hershey stock. Now, as it faces analyst skepticism, Hershey must find a way to grow as one of its sales strategies becomes less viable.
BRK.A SHOP HSYFB PG AMZN TVIX HSY
Online crafts marketplace Etsy Inc. ETSY 26.25% said it is increasing the transaction fees it charges, cheering Wall Street investors but angering some of the merchants that sell on the site.
Everything cryptocurrency related peaked in late 2017. At that point in time, bitcoin prices were around $19,000. Ethereum prices were around $1,400. Ripple prices were around $3. Bitcoin cash was priced around $3,700. And litecoin was trading around $360.
SHOP GOOGL GRUB NFLX GOOG
The U.S. retail sector is back with a bang with SPDR S&P Retail ETF (XRT - Free Report) rising 5.4%, trumping the S&P 500’s 1.9% gains year to date (as of Jun 5). While the growing acceptance of online retailing cannot be denied, struggles seem to be over for department stores.
SHOP RTH RETL XRT
Adobe Systems announced plans to acquire Magento Inc. for $1.68 billion. Magento, a digital commerce software category leader, competes with Digital River, IBM, Oracle, Salesforce and SAP.
SHOP DRIV KO ADBE ORCL
A month has gone by since the last earnings report for Shopify Inc. (SHOP - Free Report) . Shares have added about 12.2% in that time frame.
2017-11-09 - Asif
Shopify provides the leading cloud-based, multi-channel commerce platform designed for small and medium-sized businesses. Merchants use its software to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts, and marketplaces. As the number of channels over which merchants transact continues to expand, the importance of a multi-channel platform that is both fully integrated and easy to use increases. The Shopify platform provides merchants with a single view of their business and customers across all of their sales channels and enables them to manage products and inventory, process orders and payments, ship orders, build customer relationships and leverage analytics and reporting all from one integrated back office. Commerce transacted over mobile devices continues to grow more rapidly than desktop transactions. For several years Shopify has focused on enabling mobile commerce and its merchants ...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to SHOP / Shopify Inc. on message board site Silicon Investor.
as of ET